Valuation check: USRM's profit margin is -3483.21%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Dec 2022
Trailing 12 months ending Dec 2022
U.S. Stem Cell (USRM) currently reports a profit margin of -3483.21% as of December 2022. That compares with -1637.58% in the prior-year period — down 112.7% year over year. That is below the Healthcare sector average of 17.63%. Use the charts on this page to explore U.S. Stem Cell's profit margin history and peer comparisons.
U.S. Stem Cell's profit margin decreased from -1637.58% to -3483.21% — a 112.7% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
U.S. Stem Cell's profit margin of -3483.21% is lower than the Healthcare sector average of 17.63%. That is roughly 19859.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but U.S. Stem Cell's current -3483.21% should be judged against Healthcare norms (sector average: 17.63%) and against USRM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -3483.21%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for U.S. Stem Cell, and consider following USRM for alerts when major investors trade the stock.